Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Non-Comparative Expanded Access Study of the Raf-Kinase Inhibitor Sorafenib (Bay 43-9006) as a Subsequent to First-Line Therapy in Patients with Advanced Renal Cell Carcinoma, Assessing Safety and Efficacy.

Next Previous
Trial Profile

An Open-Label, Non-Comparative Expanded Access Study of the Raf-Kinase Inhibitor Sorafenib (Bay 43-9006) as a Subsequent to First-Line Therapy in Patients with Advanced Renal Cell Carcinoma, Assessing Safety and Efficacy.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms AUS1
  • Sponsors Bayer

Most Recent Events

  • 12 Feb 2020 Status changed from recruiting to completed.
  • 30 Aug 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top